Developing precision therapies against hard-to-drug targets
Hummingbird Bioscience is focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes. Enabled by their proprietary Rational Antibody Discovery platform, the company discovers and engineers precision therapies against optimal yet elusive epitopes that have not been successfully drugged, unlocking novel mechanisms of action. The company is advancing a pipeline of potentially first- and best-in-class precision therapies in oncology and autoimmunity, in collaboration with global partners in academia and industry.
